EVALUATION OF CHOP REGIMEN TOXICITY IN PATIENTS WITH NON HODGKIN’S LYMPHOMA

Non-Hodgkin’s lymphoma (NHL) is the most common hematologic cancer among adults in the world. Evidences imply that multicyclic CHOP chemotherapy may improve the treatment outcome in intermediate grade NHL. The objective is to evaluate the adverse effects of CHOP therapy on hematological and gastrointestinal parameters with each cycle of chemotherapy. This is a prospective study conducted at Oncological Service at University Hospital Centre “Mother Theresa” with NHL patients receiving 6-8 cycles of CHOP chemotherapy. After 8 chemotherapeutic cycles, 20% patients represented healthy living, whereas 64% patients showed grade 1 and 16% subjects showed grade 2 adverse events, p